Zepbound (Tirzepatide) Approved as a once-weekly injection, Zepbound targets two hormones, GLP-1 and GIP, for increased weight loss results
Consistent with previous studies, LPD mice had reduced levels of circulating IGF-1 (Figure 3B, Table 3), concomitant with decreased liver Igf1 expression (Figure 3C, Table 3) and production (Figure 3D, Table 3)
It also helps to form myelin sheath to protect nerve cells and conduct nerve impulses, and lowers homocysteine levels thereby reducing the risk of strokes or heart attacks
Eli Lillys competing drug, Mounjaro (tirzepatide), is also approved for diabetes treatment, with a weight loss counterpart marketed as Zepbound
Next, our expert care team tackles insurance verification and prior authorizations to streamline your semaglutide weight loss journey